Investment Newsletters

JUNO

Juno Therapeutics Inc (JUNO)’s Multiple Sources of Technology May Prove To Be A Competitive Advantage Over Time: J.P. Morgan

Juno Therapeutics Inc (NASDAQ:JUNO) shares have taken off, adding 13.72% to trade at $60.

Jason Cohen — June 2, 2015, 10:53 AM EDT

Stock Update (NASDAQ:JUNO): Juno Therapeutics Inc Adds Antibody Engineering Capabilities Through Acquisition of X-BODY

Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced that it has …

Corey Williams — June 2, 2015, 7:39 AM EDT

J.P. Morgan Provides Key Takeaways From Juno Therapeutics Inc ASCO Presentations

J.P.

Jason Cohen — June 1, 2015, 8:29 PM EDT

Stock Update (NASDAQ:JUNO): Juno Therapeutics Inc’s Investigational CAR T Cell Product Candidate Demonstrates Encouraging Clinical Responses in Patients With B-Cell Cancers

Juno Therapeutics Inc (NASDAQ:JUNO) announced that clinical data from a chimeric antigen receptor (CAR) T cell product candidate, JCAR014, demonstrated encouraging clinical responses in patients …

Corey Williams — June 1, 2015, 10:23 AM EDT

Stock Update (NASDAQ:JUNO): Juno Therapeutics Inc Appoints Dr. Hyam I. Levitsky as Chief Scientific Officer

Juno Therapeutics Inc (NASDAQ:JUNO), a biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, announced the appointment of …

Corey Williams — May 28, 2015, 4:17 PM EDT

J.P. Morgan Shines Light on Juno Therapeutics Inc (JUNO) Deal With Editas Medicine

J.P.

Jason Cohen — May 27, 2015, 5:49 PM EDT

Company Update (NASDAQ:JUNO): Juno Therapeutics Inc and Editas Medicine Announce Exclusive Collaboration to Create Next-Generation CAR T and TCR Cell Therapies

Juno Therapeutics Inc (NASDAQ:JUNO), a leading biopharmaceutical company focused on re-engaging the body’s immune system to revolutionize the treatment of cancer, and Editas …

Corey Williams — May 27, 2015, 8:04 AM EDT